Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 17Lymphoma 16Multiple Myeloma 13Neoplasm Metastasis 10Leukemia, Myeloid, Acute 10Melanoma 9Lung Neoplasms 9Prostatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 6Lymphoma, Non-Hodgkin 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Neuroblastoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Follicular 4Burkitt Lymphoma 4Wilms Tumor 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Sarcoma 3Rhabdoid Tumor 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precancerous Conditions 3Ovarian Neoplasms 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

Cyclophosphamide 27fludarabine phosphate 19Whole-Body Irradiation 18Peripheral Blood Stem Cell Transplantation 18Etoposide 17Rituximab 15Brentuximab Vedotin 15Mycophenolic Acid 14Tacrolimus 13Doxorubicin 12Vincristine 11Prednisone 11Methotrexate 11Busulfan 11Melphalan 9Antilymphocyte Serum 9Cyclosporine 8Filgrastim 6Carboplatin 6Sirolimus 5Radiotherapy 5Lenalidomide 5Gene Expression Profiling 5Cytarabine 5merphos 4Vorinostat 4Immunohistochemistry 4Ifosfamide 4Gemcitabine 4Flow Cytometry 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large-Cell, Anaplastic × Biopsy × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡